Pharmamel
CompanySpainFounded 2014
Pharmamel develops one asset, approved (melatonin in autism spectrum disorder). Mostly small molecule acting on MTNR1A, Oxidative stress and ROS signalling and inflammation; based in Spain, founded in 2014.
- 1
- Asset
- Furthest
- Approved
- 1
- Trial
- 0
- Signals
Pipeline
1Melatonin receptor agonist that regulates circadian rhythm and sleep-wake cycles.
Approved, Small molecule, MTNR1A, Oxidative stress and ROS signalling, autism spectrum disorder, autistic disorder
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials1
- Similar companies6
Updated 8 Oct 2026 · 21 sources